1. Blackstone EA, Joseph PF (2013) The economics of biosimilars. Am Health Drug Benefits 6:469–478
2. Mellstedt H, Niederwieser D, Ludwig H (2008) The challenge of biosimilars. Ann Oncol 19:411–419.
https://doi.org/10.1093/annonc/mdm345
3. Chopra R, Lopes G (2017) Improving access to cancer treatments: the role of biosimilars. J Glob Oncol 2016:008607.
https://doi.org/10.1200/JGO.2016.008607
4. US Food and Drug Administration (2015) Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry.
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf
. Accessed 16 August 2018
5. European Medicines Agency (2014) Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues.
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf
. Accessed 16 August 2018